Drug intelligence / Profile preview

anti-IL-25 antibody

Development stage
Unknown
Lead developer
Kanova
Modality
Antibody-Based Therapeutics
Administration
Subcutaneous, Intravenous
01

Overview

An anti-IL-25 antibody is a monoclonal antibody designed to target and neutralize interleukin-25 (IL-25, also known as IL-17E), an upstream alarmin cytokine that plays a critical role in initiating and amplifying type 2 (Th2) immune responses. By binding to IL-25, the antibody prevents its interaction with the heterodimeric receptor complex composed of IL-17RA and IL-17RB. This blockade suppresses the downstream activation of type 2 innate lymphoid cells (ILC2s) and Th2 helper T cells, thereby inhibiting the release of key pro-inflammatory cytokines such as IL-4, IL-5, and IL-13. Anti-IL-25 antibodies are being investigated for the treatment of various Th2-mediated inflammatory and allergic diseases, including asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF).

Other names
IL-25 antibodyIL25 antibodyIL 25 antibodyanti-IL-17E antibodyanti-IL17E antibodyanti-IL 17E antibodyanti-interleukin-25 antibodyanti-interleukin25 antibodyanti-interleukin 25 antibodyinterleukin-25 antibodyinterleukin25 antibodyinterleukin 25 antibody
02

Targets

IL-17R (Interleukin 17 Receptor)IL17RB (Interleukin-17 receptor B)IL25 (IL-25)

Beyond the preview

Go deeper on anti-IL-25 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IL-25 antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call